Alkermes plc
ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and preventionā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$27.64
Price-0.47%
-$0.13
1Y
Price
Market Cap
$4.606b
Mid
Price/Earnings 3y Avg5y Avg
19.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+19.9%
EBITDA Margin+12.8%
Net Profit Margin+44.2%
Free Cash Flow Margin+19.9%
EBITDA Margin+12.8%
Net Profit Margin+44.2%
Free Cash Flow MarginRevenue
$1.476b
-5.2%
1y CAGR+12.7%
3y CAGR+8.2%
5y CAGREarnings
$241.664m
-34.2%
1y CAGR+97.9%
3y CAGR+16.3%
5y CAGREPS
$1.43
-34.1%
1y CAGR+95.2%
3y CAGR+15.6%
5y CAGRBook Value
$1.819b
$2.530b
Assets$710.960m
Liabilities$69.999m
DebtDebt to Assets
2.8%
0.2x
Debt to EBITDAFree Cash Flow
$480.334m
+18.4%
1y CAGR+728.7%
3y CAGR+515.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company